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Background
Leukemic cells originate from hypoxic bone marrow, which protects them from anti-can-
cer drugs. Although many factors that cause drug resistance in leukemic cells have been 
studied, the effect of hypoxia on drug-induced apoptosis is still poorly understood. 
Methods
In this study, we examined the effect of hypoxia on anti-leukemic drug resistance in leuke-
mic cell lines treated with cobalt chloride (CoCl2), a hypoxia-mimetic agent. Cellular pro-
liferation was evaluated using the methyl thiazolyl tetrazolium (MTT) assay. Flow cy-
tometry analysis and western blots were performed to investigate apoptosis-related 
proteins. 
Results
Unlike its previously known apoptotic effect, the expression of HIF-1α increased the sur-
vival rate of human promyelocytic leukemia HL-60 cells when these cells were exposed 
to anti-leukemic drugs; these effects were mediated by heat-shock protein HSP70 and 
the pro-apoptotic protein Bax. 
Conclusion
These findings may provide new insights for understanding the mechanisms underlying 
hypoxia and for designing new therapeutic strategies for acute myeloid leukemia.
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INTRODUCTION
  Arsenic trioxide (ATO, As2O3) is a traditional Chinese 
medicine that has been used to treat several diseases such 
as anemia, dyspepsia, and some tumors [1]. ATO promotes 
elimination of acute promyelocytic leukemia (APL) by the 
induction of apoptosis [2]. The apoptotic effect of ATO is 
not restricted to APL but is also observed in other malignant 
cells including those of non-APL acute myeloid leukemia, 
myeloma, chronic myeloid leukemia, esophageal and ovarian 
carcinomas, and neuroblastoma [3-5].
  Hypoxia or low oxygen tension is present at inflammatory 
sites, solid tumors, and bone marrow. To adapt to hypoxia, 
cells express many types of genes that are related to angio-
genesis, mobility, and glucose metabolism through the hypo-
xia-inducible factor-1α (HIF-1α) [6-8]. HIF-1α is degraded 
by ubiquitination in the proteosome under conditions of 
normal oxygen tension (normoxia) even though it is con-
stantly expressed. However, under hypoxia, HIF-1α is stabi-
lized because of the lack of oxygen, and bound to con-
stitutively expressed HIF-1β (ARNT). The HIF-1α/β hetero-
dimer is bound to DNA at a specific recognition site known 
as the hypoxia response element (HRE), which initiates tran-
scription of target genes [9, 10]. HIF-1α can be also stabilized 
by iron chelators and metal ions such as Co
2+, Ni
2+, and 
Mn
2+ even under normoxia. In this study, we used cobalt 
chloride (CoCl2), a well-established chemical inducer of 
HIF-1α, to induce hypoxia-like responses [11].
  Leukemic cells originate from bone marrow, which acts 
as a physical barrier to anticancer drugs. In addition, the 
microenvironment of bone marrow transmits survival signals 
that mediate adhesion through integrins and CD44 to fi-
bronectin and hyaluronan [12, 13]. Although these factors Korean J Hematol 2010;45:158-63.
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Fig. 1. CoCl2 increases the resistance of HL-60 to Actinomycin-D (Act-D). (A) HL-60, U937, K562, and CCRF-CEM cells were cultured for 8 hrs with 
or without CoCl2 (100 μM) and for additional 15 hrs in the presence of Act-D (1 μg/mL). Cells were then analyzed for PI negative population by flow 
cytometry. CTR, control. (B) HL-60 cells were pre-treated with various doses of CoCl2 for 8 hrs and then cultured for 15 hrs with indicated doses
of Act-D. Cell viability was evaluated by the MTT assay. The relative viable cell number was calculated as the ratio of each optical density (OD) to 
the control OD. Results are expressed as relative viability±SEM. An asterisk (*) represents statistical significance when the P-value is lower than 
0.05. 
i n c r e a s e  l e u k e m i c  c e l l  r e s i s t a n c e  i n  t h e  b o n e  m a r r o w  t o  
chemotherapeutic drugs, the survival effect of hypoxic bone 
marrow microenvironment on leukemic cells is still not 
understood.
  Many previous studies have primarily focused on the apop-
totic effect of hypoxia that affects cell survival and differ-
entiation [14, 15]. The anti-apoptotic effect of hypoxia on 
several cell types has also been assessed [16-18]. Here, we 
investigated the relationship between hypoxia (using a mim-
etic agent) and drug resistance in leukemic cells to elucidate 
the contribution of hypoxic bone marrow microenvironment 
to failure of chemotherapeutic treatment.
MATERIALS AND METHODS
1. Cell culture and reagents
  Four human leukemic cell lines (HL-60, APL; U937, acute 
myeloid leukemia; CCRF-CEM, acute lymphoblastic leuke-
mia; K562, chronic myelogenous leukemia) were purchased 
from the Korean Cell Line Bank (KCLB; Seoul, Korea). All 
cells were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) 
supplemented with 10% FBS (Hyclone Laboratories, Inc., 
Logan, UT) and penicillin-streptomycin (Invitrogen). To in-
duce expression of HIF-1α, cells were cultured with a cobalt 
chloride (CoCl2; Sigma, St. Louis, MO). 
2. Cell proliferation assay: MTT assay
  The cell proliferation rate was determined by measuring 
the absorbance of the MTT dye (3-[4,5-dimethylthiazol- 
2yl]-2,5-diphenyltetrazolium bromide; Sigma) in living cells. 
Cells were inoculated in each well of a 12- or 24-well tissue 
culture plate. After 3 d, the MTT solution was added to 
each well and the plates were incubated for 3 or 4 hr at 
37
oC. Supernatants were then removed, and 100 μL of 0.04 
N HCl-isopropanol was added to solubilize the formazan 
crystal formed by succinate dehydrogenase activity in viable 
cells. The plates were shaken at room temperature for 30 
min, and then the absorbance at 540 nm was measured 
on a ThermoMAX microplate reader (Molecular Devices, 
Sunnyvale, CA).
3. Detection of apoptosis
  Apoptotic cell death was detected by an annexin V- 
FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, 
CA) or a caspase-3 detection kit (BD Pharmingen) according 
to the manufacturer’s instructions. For the annexin V- 
FITC/PI kit, after adding 5 μL annexin V-FITC and 5 μL 
propidium iodide (PI), cells were incubated for 15 min at 
room temperature in the dark. Flow cytometry analysis was 
carried out within 1 hr. For caspase-3 detection, cells were 
washed twice with cold PBS and then resuspended in a 
Cytofix/Cytoperm solution and incubated for 20 min on ice. 
Following washing with a Perm/Wash buffer, cells were 
resuspended in a Perm/Wash buffer containing an anti-active 
caspase-3 antibody and incubated for 30 min at room 
temperature. After washing with a Perm/Wash buffer, the 
cells were prepared for flow cytometry analysis.
4. Western blot analysis
  Total proteins were extracted by Pro-Prep (InTron Inc., 
Seoul, Korea) supplemented with phosphatase inhibitors 
(Sigma) and then normalized with a Micro BCA reagent 
(Pierce, Rockford, IL). Protein samples (30 μg each) were 
run on a 10% SDS-PAGE gel and transferred to PROTRAN- 
NC (Whatman, Clifton, NJ). Blots were blocked with 5% 
skim milk in TBST (0.1% Tween 20 in Tris-Buffered Saline) 
at room temperature for 1 hr and then incubated with Bax, Korean J Hematol 2010;45:158-63.
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Fig. 2. CoCl2 increases the resistance of HL-60 to anti-leukemic drugs. HL-60, U937, K562, and CCRF-CEM cells were cultured for 15 hrs in the 
presence or absence of CoCl2. Cells were then cultured for another 15 hrs with or without (A) ATO (2.5 μM), (B) 17-AAG (1 μM), (C) valproic acid
(5 mM), or (D) cytarabine (1 μM). Cell viability was analyzed by the MTT assay. The relative viable cell number was calculated as the ratio of each 
OD to the OD of cells treated with drug alone (set as 1.0). Results are expressed as relative viability±SEM. Asterisk (*) indicates statistical 
significance when the P-value is lower than 0.05.
HSP70, HSP90, Bcl-2, ERK, phospho-ERK, p38, phospho- 
p38,  α-tubulin (Cell Signaling Technology Inc., Danvers, 
MA), or HIF-1α (BD Pharmingen) antibodies in blocking 
buffer (1：1,000) at 4
oC overnight. After washing 3 times 
with TBST, blots were incubated with horseradish-peroxidase 
(HRP)-conjugated secondary antibodies in blocking buffer 
(1：5,000) at room temperature for 1 hr. Blots were then 
washed 5 times with TBST and developed with the Super-sig-
nal reagent (Pierce).
5. HIF-1α inhibition assay
  HL-60 cells were pre-treated with cadmium chloride (20 
μM, CdCl2; Sigma) for 12 hr then cultured for 48 hr with 
CoCl2. Cell viability was assessed by the MTT assay, and 
HIF-1α expression was checked by western blot analysis 
as described above. The experiments were repeated 3 separate 
times under each set of conditions.
6. Statistical analysis 
  Data were expressed as the mean±SEM (standard error 
of the mean) of 3 experiments and were analyzed with an 
unpaired two-tailed Student’s t-test. Significance was estab-
lished when P＜0.05.
RESULTS
1. CoCl2 increases resistance of HL-60 cells to actinomycin-D
  Leukemia cells originating from the bone marrow are un-
der hypoxic conditions, which is in contrast to normoxic 
peripheral blood. We first investigated whether hypoxia-like 
conditions increased resistance of leukemic cells to actino-
mycin-D (Act-D)-induced oxidative stress-dependent apop-
tosis in U937, HL-60, CCRF-CEM, and K562 cells [19]. 
Among the 4 different leukemic cell lines, HL-60 cells were 
resistant to Act-D-induced cell death by treatment with 
CoCl2 (PI negative population: Act-D-treated, 5.8% vs. Act- 
D/CoCl2-treated, 47.09%) (Fig. 1). The protective effect of 
CoCl2 was significantly increased at higher doses of Act-D 
(0.125 and 1.0 μg/mL). These results indicate that CoCl2 
increases resistance of HL-60 cells to Act-D-induced cell 
death.Korean J Hematol 2010;45:158-63.
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Fig. 3. CoCl2 decreases the apoptotic rate of HL-60 cells through the HSP70/Bax pathway. (A) HL-60 or K562 cells were cultured for 24 hrs in the 
presence or absence of CoCl2. Expression levels of HSP90, HSP70, and Bax were analyzed by western blotting. An α-tubulin antibody was used as 
an internal control. (B) HL-60 cells were cultured with indicated dose of CoCl2 for 24 hrs. The expression levels of Bax, Bcl-2, ERK, phospho-ERK,
HSP70, HSP90, p38, and phospho-p38 were analyzed by western blotting. (C) HL-60 cells were cultured with or without CoCl2 in the presence of 
ATO for 24 hrs. The amount of cleaved caspase-3 was assessed by flow cytometry. (D) HL-60 cells were cultured with or without ATO in the presence
or absence of CoCl2 for 24 hrs. Cells were stained with annexin V/PI and then analyzed by flow cytometry.
2. CoCl2 increases resistance of HL-60 cells to anti-leukemic 
drugs
  Next, we tested the resistance of leukemic cells to several 
anti-leukemic drugs that are used for leukemia treatment 
because development of drug resistance is the most important 
factor associated with the failure of leukemic cell chemo-
therapeutic treatments. Each cell line was treated with an 
anti-leukemic drug: ATO (A), 17-(allylamino)-17-demethox-
ygeldanamycin (17-AAG), an HSP90 inhibitor (B), valproic 
acid (C), and cytarabine (D), in the presence or absence 
of CoCl2 (Fig. 2). Among the 4 cell lines, HL-60 cells were 
resistant under CoCl2-treatment conditions to each of the 
above anti-leukemic drugs (ATO, 1.41-fold increase, P= 
0.009; 17-AAG, 1.54-fold increase, P=0.002; valproic acid, 
1.19-fold increase, P=0.007; cytarabine, 1.18-fold increase, 
P=0.053). K562 was resistant to only 17-AAG. In contrast, 
the treatment of CCRF-CEM cells with CoCl2 strongly de-
creased cell viability in the presence and absence of the 
anti-leukemic drugs (Fig. 1A and Fig. 2). 
3. CoCl2 prevents apoptotic cell death in HL-60 cells via regu-
lation of the apoptotic pathway
To verify whether hypoxia-like conditions inhibit HL-60 
cell death by blocking the apoptotic pathway, we investigated 
the expression level of several apoptosis-related genes by 
western blot analysis based on previous results in 4 cell 
lines. Intriguingly, CoCl2 affects the expression of both the 
pro-apoptotic protein Bax (down-regulation) and the heat 
shock protein HSP70 (up-regulation), which are the main 
regulators of ATO-induced cell death [20, 21], but did not 
affect the expression of Bcl-2 or HSP90 (Fig. 3A, B). Moreover, 
we found that CoCl2 increased the phosphorylation levels 
of survival-related ERK and p38 (Fig. 3B). However, in K562 
cells (Fig. 3A), U937, and CCRF-CEM cells (data not shown), 
there was no significant difference in the expression of Bax 
and HSP70 between CoCl2-treated and -untreated con-
ditions. In addition, the level of cleaved caspase-3 was de-
creased with CoCl2 treatment in the presence of ATO, as 
compared to ATO in the absence of CoCl2 (Fig. 3C, mean 
fluorescence intensity (MFI); 152 vs. 213). Similarly, annexin 
V-FITC/PI analysis indicated that CoCl2 treatment decreased Korean J Hematol 2010;45:158-63.
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Fig. 4. The expression of HIF-1α increases the resistance of HL-60 cells
to ATO. (A) HL-60 cells were cultured in the presence of the indicated 
doses of CoCl2 for 24 hrs. Expression of HIF-1α was then analyzed by 
western blotting. A β-actin antibody was used as an internal control. (B)
HL-60 cells were cultured in the presence or absence of CdCl2 and/or 
CoCl2 for 12 hrs and with ATO for additional 48 hrs. Cell viability was 
analyzed by the MTT assay. The relative viable cell number was 
calculated as the ratio of each OD to the control OD. Results are 
expressed as relative viability±SEM. Two asterisks (*) represents 
statistical significance when the P-value is lower than 0.01.
the apoptotic population of ATO-treated cells (Fig. 3D, an-
nexin V/PI double positive: 25% vs. 15%). Collectively, these 
results demonstrate that CoCl2 treatment prevents apoptosis 
of ATO-treated HL-60 cells through the regulation of HSP70 
and Bax.
4. HIF-1α induction by CoCl2 increases the survival rate of 
HL-60 cells
  As shown in Fig. 4, CoCl2 strongly increased the expression 
level of HIF-1α in a CoCl2-dose dependent manner (Fig. 
4A) without significant cell death (data not shown). To de-
termine if the effect of CoCl2 on decreased apoptosis was 
mediated by HIF-1α, we performed an inhibition assay using 
CdCl2, an inhibitor of HIF-1α activation [22]. CdCl2 effec-
tively decreased the expression level of HIF-1α (Fig. 4B). 
While resistance of HL-60 cells was significantly increased 
more than 2-fold by CoCl2, treatment with CdCl2 reduced 
the survival rate of ATO-treated cells. These results show 
that the induction of HIF-1α by CoCl2 increases resistance 
of HL-60 cells to ATO.
DISCUSSION
  Under hypoxia, the expression of migration and angio-
genesis-related genes can be an important survival strategy 
in solid cancer cells. In contrast, some cells like immune 
cells in inflammatory sites and hematopoietic progenitor 
cells in bone marrow stay in hypoxic sites. In particular, 
the bone marrow provides both a physical barrier and surviv-
al signals to resident leukemic cells [12, 13]. Therefore, its 
protective effect increases resistance to anti-leukemic drugs. 
However, the effect of the hypoxic bone marrow micro-
environment on leukemic cell survival is still unknown, 
although we previously reported that hypoxia decreases the 
migration rate of leukemia cells [23]. In this study, we exam-
ined the relationship between leukemic cell survival and 
HIF-1α, which is an essential effector of hypoxia. 
  First, we determined that CoCl2 treatment dramatically 
increased resistance of HL-60 cells to Act-D, an inducer 
of apoptosis, in a dose-dependent manner. Although the 
survival rate of HL-60 cells was not high due to the potent 
effect of Act-D, CoCl2 treatment strongly increased the PI 
negative population more than 7-fold. We then examined 
the effect of CoCl2 on cells treated with anti-leukemic drugs. 
CoCl2 increased resistance of HL-60 cells to ATO, 17-AAG, 
valproic acid, and cytarabine. However, we did not observe 
a protective effect of CoCl2 on other leukemia cell lines. 
For example, CCRF-CEM cells were relatively sensitive to 
CoCl2 treatment. These observations indicate that the an-
ti-apoptotic effect of CoCl2 depends on the specific leukemic 
cell type.
  ATO is currently used for acute promyeloid leukemia ther-
apy due to its potential as an inducer of cell death through 
regulation of apoptosis-related molecules [2]. Results from 
the annexin V/PI analysis and caspase-3 activation assay 
indicated that CoCl2 treatment reversed the ATO-induced 
apoptotic rate of acute promyelocytic HL-60 cells. Although 
it is known that ATO induces cell death through the regu-
lation of HSP70, HSP90, Bax, and Bcl-2 molecules [20, 21], 
our results indicate that CoCl2 regulates only HSP70 and 
Bax in ATO-treated HL-60 cells. Because the HSP70/Bax 
axis plays a critical role in the intrinsic apoptotic pathway 
[24, 25], its regulation by CoCl2 can be a potential mechanism 
to explain our observations. CoCl2 treatment also results 
in the phosphorylation and therefore activation of ERK and 
p38, which are related to increased survival of leukemic 
cells [26]. Data from the HIF-1α inhibition assay indicates 
that the survival effects of CoCl2 on ATO-treated HL-60 
cells are strongly correlated with the expression of HIF-1α.
  In some patients with leukemia, after initial chemo-
therapy, a small number of leukemic cells survive, develop 
resistance to treatment, and the disease returns. The most 
common relapse site of leukemia is the bone marrow where 
the leukemia originated. In addition to survival benefits pro-
vided by the bone marrow because of transmission of several Korean J Hematol 2010;45:158-63.
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survival factors to leukemic cells, such as cytokines and adhe-
sion molecules [12, 13, 27], our results indicate that the 
hypoxic microenvironment of bone marrow may be a critical 
survival factor for leukemic cells. These discoveries provide 
new insights for understanding the mechanisms underlying 
hypoxia and for designing new therapeutic strategies for 
acute myeloid leukemia.
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